169 related articles for article (PubMed ID: 37395842)
1. Patient centered radiology: investigating 3 Tesla whole body MRI acceptance in cancer patients.
Rossi A; Prochowski Iamurri A; Diano D; Oboldi D; Sintuzzi E; Maurizio L; Andalò A; Cavallucci M; Ferroni F; Amadori E; Barone D; Petralia G
Radiol Med; 2023 Aug; 128(8):960-969. PubMed ID: 37395842
[TBL] [Abstract][Full Text] [Related]
2. Predictors of patient preference for either whole body magnetic resonance imaging (WB-MRI) or CT/ PET-CT for staging colorectal or lung cancer.
Miles A; Evans RE; Halligan S; Beare S; Bridgewater J; Goh V; Janes SM; Navani N; Oliver A; Morton A; Morris S; Rockall A; Taylor SA;
J Med Imaging Radiat Oncol; 2020 Aug; 64(4):537-545. PubMed ID: 32410378
[TBL] [Abstract][Full Text] [Related]
3. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.
Machado Medeiros T; Altmayer S; Watte G; Zanon M; Basso Dias A; Henz Concatto N; Hoefel Paes J; Mattiello R; de Souza Santos F; Mohammed TL; Verma N; Hochhegger B
Eur Radiol; 2020 Jul; 30(7):3641-3649. PubMed ID: 32125513
[TBL] [Abstract][Full Text] [Related]
4. Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma.
Albano D; Patti C; Lagalla R; Midiri M; Galia M
J Magn Reson Imaging; 2017 Apr; 45(4):1082-1089. PubMed ID: 27603267
[TBL] [Abstract][Full Text] [Related]
5. [Informativeness of whole-body diffusion-weighted magnetic resonance imaging and positron emission tomography with computed tomography in follicular lymphoma].
Nesterova ES; Yatsyk GA; Lutsik NS; Kravchenko SK; Sudarikov AB; Krasil'nikova IV; Gemdzhian EG; Kovrigina AM
Ter Arkh; 2020 Sep; 92(7):55-62. PubMed ID: 33346445
[TBL] [Abstract][Full Text] [Related]
6. Whole body MRI with Diffusion Weighted Imaging versus 18F-fluorodeoxyglucose-PET/CT in the staging of lymphomas.
Maccioni F; Alfieri G; Assanto GM; Mattone M; Gentiloni Silveri G; Viola F; De Maio A; Frantellizzi V; Di Rocco A; De Vincentis G; Pulsoni A; Martelli M; Catalano C
Radiol Med; 2023 May; 128(5):556-564. PubMed ID: 37145214
[TBL] [Abstract][Full Text] [Related]
7. Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma.
Mesguich C; Hulin C; Latrabe V; Lascaux A; Bordenave L; Hindié E; Marit G
Ann Hematol; 2020 Dec; 99(12):2869-2880. PubMed ID: 32951093
[TBL] [Abstract][Full Text] [Related]
8. Staging of colon cancer: whole-body MRI vs. whole-body PET-CT--initial clinical experience.
Squillaci E; Manenti G; Mancino S; Cicciò C; Calabria F; Danieli R; Schillaci O; Simonetti G
Abdom Imaging; 2008; 33(6):676-88. PubMed ID: 18373114
[TBL] [Abstract][Full Text] [Related]
9. High-resolution whole-body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomography-computed tomography: experience on a 32-channel system.
Schmidt GP; Baur-Melnyk A; Herzog P; Schmid R; Tiling R; Schmidt M; Reiser MF; Schoenberg SO
Invest Radiol; 2005 Dec; 40(12):743-53. PubMed ID: 16304476
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic performance of
Basha MAA; Hamed MAG; Refaat R; AlAzzazy MZ; Bessar MA; Mohamed EM; Ahmed AF; Tantawy HF; Altaher KM; Obaya AA; Afifi AHM
Jpn J Radiol; 2018 Jun; 36(6):382-393. PubMed ID: 29671193
[TBL] [Abstract][Full Text] [Related]
11. Patient preferences for whole-body MRI or conventional staging pathways in lung and colorectal cancer: a discrete choice experiment.
Miles A; Taylor SA; Evans REC; Halligan S; Beare S; Bridgewater J; Goh V; Janes S; Navani N; Oliver A; Morton A; Rockall A; Clarke CS; Morris S;
Eur Radiol; 2019 Jul; 29(7):3889-3900. PubMed ID: 30937589
[TBL] [Abstract][Full Text] [Related]
12. Staging performance of whole-body DWI, PET/CT and PET/MRI in invasive ductal carcinoma of the breast.
Catalano OA; Daye D; Signore A; Iannace C; Vangel M; Luongo A; Catalano M; Filomena M; Mansi L; Soricelli A; Salvatore M; Fuin N; Catana C; Mahmood U; Rosen BR
Int J Oncol; 2017 Jul; 51(1):281-288. PubMed ID: 28535000
[TBL] [Abstract][Full Text] [Related]
13. Investigating cancer patient acceptance of Whole Body MRI.
Oliveri S; Pricolo P; Pizzoli S; Faccio F; Lampis V; Summers P; Petralia G; Pravettoni G
Clin Imaging; 2018; 52():246-251. PubMed ID: 30170274
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic performance of FDG-PET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT.
Herrmann K; Queiroz M; Huellner MW; de Galiza Barbosa F; Buck A; Schaefer N; Stolzman P; Veit-Haibach P
BMC Cancer; 2015 Dec; 15():1002. PubMed ID: 26699124
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic bone imaging in patients with prostate cancer: patient experience and acceptance of NaF-PET/CT, choline-PET/CT, whole-body MRI, and bone SPECT/CT.
Dyrberg E; Larsen EL; Hendel HW; Thomsen HS
Acta Radiol; 2018 Sep; 59(9):1119-1125. PubMed ID: 29313360
[TBL] [Abstract][Full Text] [Related]
16. The added value of whole-body magnetic resonance imaging in the management of patients with advanced breast cancer.
Zugni F; Ruju F; Pricolo P; Alessi S; Iorfida M; Colleoni MA; Bellomi M; Petralia G
PLoS One; 2018; 13(10):e0205251. PubMed ID: 30312335
[TBL] [Abstract][Full Text] [Related]
17. Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology.
Schmidt GP; Kramer H; Reiser MF; Glaser C
Top Magn Reson Imaging; 2007 Jun; 18(3):193-202. PubMed ID: 17762383
[TBL] [Abstract][Full Text] [Related]
18. Optimization of whole-body 2-[
Burns R; Mulé S; Blanc-Durand P; Tofighi M; Belhadj K; Zerbib P; Le Bras F; Baranes L; Haioun C; Itti E; Luciani A
Eur Radiol; 2022 May; 32(5):3085-3096. PubMed ID: 34842956
[TBL] [Abstract][Full Text] [Related]
19. [Whole-body staging of malignant melanoma: advantages, limitations and current importance of PET-CT, whole-body MRI and PET-MRI].
Pfannenberg C; Schwenzer N
Radiologe; 2015 Feb; 55(2):120-6. PubMed ID: 25589421
[TBL] [Abstract][Full Text] [Related]
20. Multiparametric whole-body 3.0-T MRI in newly diagnosed intermediate- and high-risk prostate cancer: diagnostic accuracy and interobserver agreement for nodal and metastatic staging.
Johnston EW; Latifoltojar A; Sidhu HS; Ramachandran N; Sokolska M; Bainbridge A; Moore C; Ahmed HU; Punwani S
Eur Radiol; 2019 Jun; 29(6):3159-3169. PubMed ID: 30519933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
